Simplify Logo

Full-Time

Research Associate

Lab Automation and Screening

Confirmed live in the last 24 hours

Alltrna

Alltrna

51-200 employees

Develops tRNA-based therapies for diseases

Data & Analytics
Hardware
AI & Machine Learning
Biotechnology
Healthcare

Entry

Cambridge, MA, USA

Category
Lab & Research
Life Sciences
Required Skills
Communications
Word/Pages/Docs
PowerPoint/Keynote/Slides
Requirements
  • Bachelor’s degree in Biology, Biochemistry, Molecular Biology or a related field with direct experience working in a laboratory environment
  • Hands-on experience with mammalian cell culture and transfections
  • Hands-on experience with nucleic acid extraction
  • Strong written and verbal communication skills and excellent attention to detail
  • Strong teamwork skills and ability to work in a fast-paced environment
  • Desire to learn about and implement new technologies
  • Knowledge of programs such as Microsoft Word, PowerPoint, Excel, and GraphPad Prism
Responsibilities
  • Maintain mammalian cell cultures using aseptic technique and executing cell-based assays
  • Follow standardized protocols for high to medium throughput assays, with attention to detail
  • Support high-throughput cell-based assay development; and perform cellular/molecular biology techniques including the generation of stable reporter cells, enzymatic assays, and NGS-assays.
  • Assist in processing of in vitro and in vivo samples for sequencing.
  • Document experiments, analyze data, and report results using electronic laboratory notebooks and effectively communicate findings in lab meetings
  • Execute and optimize processes within the lab to increase efficiency and effectiveness, including managing biologics inventory, lab consumables, chemicals, and equipment

Alltrna focuses on developing tRNA therapeutics to treat diseases caused by genetic mutations. Their main product involves engineered tRNAs that can recognize and read stop codons, which are errors in the genetic code that lead to the production of incomplete proteins. By delivering the correct amino acids, these tRNAs help restore the production of full-length proteins, potentially addressing a wide range of diseases linked to nonsense mutations. Unlike other biotech companies, Alltrna is the first to explore the therapeutic potential of tRNA in this way, aiming to unlock new treatment options for patients with specific genetic disorders. The goal of Alltrna is to provide effective treatments that target the root causes of diseases, improving the quality of life for those affected.

Company Stage

Series B

Total Funding

$159M

Headquarters

Cambridge, Massachusetts

Founded

2018

Growth & Insights
Headcount

6 month growth

-11%

1 year growth

-5%

2 year growth

33%
Simplify Jobs

Simplify's Take

What believers are saying

  • The recent $109 million Series B financing round provides substantial capital to advance their platform and drug candidates, indicating strong investor confidence.
  • Presentations at high-profile conferences like ASGCT and TIDES USA 2024 highlight Alltrna's growing recognition and thought leadership in the biotech community.
  • The appointment of experienced leaders like Chris Henderson as Chief Scientific Officer strengthens their executive team, potentially accelerating innovation and clinical progress.

What critics are saying

  • The novel nature of tRNA therapeutics means there is a high level of scientific and clinical uncertainty, which could delay or derail development efforts.
  • The competitive biotech landscape, especially in genetic therapies, requires continuous innovation to maintain a leading position.

What makes Alltrna unique

  • Alltrna is the first biotech company to decode tRNA biology and leverage it for therapeutic purposes, setting it apart in the biotech landscape.
  • Their focus on treating diseases caused by nonsense mutations through tRNA therapeutics is a unique approach that addresses a significant unmet medical need.
  • The integration of AI/ML tools in their platform enhances their capability to develop diverse programmable molecules, providing a technological edge over competitors.